Price
CHART BY
Frequently asked questions
What is Mirum Pharms's market capitalization?
The market capitalization of Mirum Pharms is $4.08B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Mirum Pharms?
Mirum Pharms's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.862. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Mirum Pharms's stock?
Currently, 11 analysts cover Mirum Pharms's stock, with a consensus target price of $103.10. Analyst ratings provide insights into the stock's expected performance.
What is Mirum Pharms's revenue over the trailing twelve months?
Over the trailing twelve months, Mirum Pharms reported a revenue of $471.79M.
What is the EBITDA for Mirum Pharms?
Mirum Pharms's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$17.57M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Mirum Pharms?
Mirum Pharms has a free cash flow of $44.32M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Mirum Pharms have, and what sector and industry does it belong to?
Mirum Pharms employs approximately 322 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Mirum Pharms's shares?
The free float of Mirum Pharms is 42.49M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $4.08B
- EPS (TTM)
- -$0.862
- Free Float
- 42.49M
- Revenue (TTM)
- $471.79M
- EBITDA (TTM)
- -$17.57M
- Free Cashflow (TTM)
- $44.32M
Pricing
- 1D span
- $78.86$80.28
- 52W span
- $36.96$82.58
Analyst Ratings
The price target is $103.10 and the stock is covered by 11 analysts.
Buy
11
Hold
0
Sell
0
Information
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.
- Employees
- 322
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- MIRM
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet